SPRO
Spero Therapeutics Inc

2,719
Loading...
Loading...
News
all
press releases
Best Momentum Stock to Buy for October 10th
SPRO made it to the Zacks Rank #1 (Strong Buy) momentum stock list on October 10, 2025.
Zacks·4d ago
News Placeholder
More News
News Placeholder
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease
BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.
Zacks·6d ago
News Placeholder
Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Spero Therapeutics (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·2mo ago
News Placeholder
Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease
BAYRY begins human trials for OpCT-001, an experimental cell therapy for treating primary photoreceptor diseases.
Zacks·3mo ago
News Placeholder
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
Zacks·3mo ago
News Placeholder
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.
Zacks·3mo ago
News Placeholder
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.
Zacks·4mo ago
News Placeholder
ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.
Zacks·4mo ago
News Placeholder
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why
The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.
Zacks·4mo ago
News Placeholder
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal
Zacks·5mo ago

Latest SPRO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.